RedHill Biopharma (RDHL) Operating Leases (2022 - 2024)
RedHill Biopharma (RDHL) has disclosed Operating Leases for 3 consecutive years, with $3000.0 as the latest value for Q4 2024.
- Quarterly Operating Leases fell 99.34% to $3000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $3000.0 through Dec 2024, down 99.34% year-over-year, with the annual reading at $3000.0 for FY2024, 99.34% down from the prior year.
- Operating Leases for Q4 2024 was $3000.0 at RedHill Biopharma, down from $455000.0 in the prior quarter.
- The five-year high for Operating Leases was $6.4 million in Q4 2022, with the low at $3000.0 in Q4 2024.
- Average Operating Leases over 3 years is $2.3 million, with a median of $455000.0 recorded in 2023.
- The sharpest move saw Operating Leases crashed 92.94% in 2023, then tumbled 99.34% in 2024.
- Over 3 years, Operating Leases stood at $6.4 million in 2022, then plummeted by 92.94% to $455000.0 in 2023, then crashed by 99.34% to $3000.0 in 2024.
- According to Business Quant data, Operating Leases over the past three periods came in at $3000.0, $455000.0, and $6.4 million for Q4 2024, Q4 2023, and Q4 2022 respectively.